Occudo Quantitative Strategies LP Sells 1,010 Shares of Axon Enterprise, Inc. (NASDAQ:AXON)

Occudo Quantitative Strategies LP decreased its position in Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 13.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 6,424 shares of the biotechnology company's stock after selling 1,010 shares during the quarter. Axon Enterprise comprises 0.7% of Occudo Quantitative Strategies LP's investment portfolio, making the stock its 19th largest holding. Occudo Quantitative Strategies LP's holdings in Axon Enterprise were worth $3,818,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Principal Financial Group Inc. boosted its holdings in Axon Enterprise by 33.1% in the third quarter. Principal Financial Group Inc. now owns 136,302 shares of the biotechnology company's stock worth $54,466,000 after purchasing an additional 33,869 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its position in shares of Axon Enterprise by 1.5% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 12,607 shares of the biotechnology company's stock valued at $7,493,000 after buying an additional 185 shares during the last quarter. Graypoint LLC acquired a new position in Axon Enterprise in the fourth quarter worth about $258,000. Czech National Bank raised its position in Axon Enterprise by 7.4% in the fourth quarter. Czech National Bank now owns 15,707 shares of the biotechnology company's stock worth $9,335,000 after purchasing an additional 1,082 shares in the last quarter. Finally, Winthrop Advisory Group LLC acquired a new position in Axon Enterprise in the fourth quarter worth about $236,000. Institutional investors own 79.08% of the company's stock.

Axon Enterprise Trading Up 1.2%

Shares of NASDAQ:AXON opened at $693.10 on Tuesday. The company's 50-day moving average price is $567.67 and its two-hundred day moving average price is $587.57. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63. Axon Enterprise, Inc. has a one year low of $273.52 and a one year high of $715.99. The stock has a market capitalization of $53.96 billion, a PE ratio of 179.10, a price-to-earnings-growth ratio of 5.17 and a beta of 1.24.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share for the quarter, beating the consensus estimate of $1.34 by $0.07. The firm had revenue of $603.63 million for the quarter, compared to analysts' expectations of $585.67 million. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. The business's revenue was up 31.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.15 EPS. On average, equities analysts forecast that Axon Enterprise, Inc. will post 5.8 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on AXON. JMP Securities reiterated an "outperform" rating on shares of Axon Enterprise in a research note on Tuesday, February 4th. The Goldman Sachs Group lifted their target price on shares of Axon Enterprise from $500.00 to $700.00 and gave the company a "buy" rating in a research note on Monday, January 27th. Craig Hallum cut shares of Axon Enterprise from a "buy" rating to a "cautious" rating in a research note on Monday, March 10th. Barclays increased their price target on shares of Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a research note on Friday. Finally, Northcoast Research cut shares of Axon Enterprise from a "buy" rating to a "neutral" rating in a research report on Wednesday, February 19th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $640.91.

Insiders Place Their Bets

In related news, Director Jeri Williams sold 307 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $552.72, for a total transaction of $169,685.04. Following the sale, the director now owns 1,627 shares in the company, valued at approximately $899,275.44. This trade represents a 15.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $540.99, for a total transaction of $5,409,900.00. Following the sale, the chief executive officer now owns 3,063,982 shares in the company, valued at $1,657,583,622.18. This represents a 0.33% decrease in their position. The disclosure for this sale can be found here. Company insiders own 4.40% of the company's stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc. (NASDAQ:AXON - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.